Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
| Autor: | Hongyan Cheng, Yujia Kong, Xirun Wan, Yang Xiang, Xiaoyu Wang, Jun Zhao, Junjun Yang, Wei Cang, Liju Zong, Yu Gu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
China medicine.medical_specialty Pyridines medicine.medical_treatment Salvage therapy Angiogenesis Inhibitors Neutropenia Antibodies Monoclonal Humanized Gastroenterology chemistry.chemical_compound Leukocytopenia Pregnancy Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols Clinical endpoint medicine Humans Apatinib Gestational Trophoblastic Disease Adverse effect Immune Checkpoint Inhibitors Aged Chemotherapy business.industry Choriocarcinoma Middle Aged medicine.disease Treatment Outcome Oncology chemistry Drug Resistance Neoplasm Female business |
| Zdroj: | The Lancet Oncology. 22:1609-1617 |
| ISSN: | 1470-2045 |
| DOI: | 10.1016/s1470-2045(21)00460-5 |
| Popis: | Summary Background Treatment options for patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia are scarce. The synergistic antitumour effect of immunotherapy and antiangiogenic drugs has been shown in many solid tumours. This phase 2 trial evaluated the activity and safety of camrelizumab (PD-1 inhibitor) plus apatinib (VEGF receptor inhibitor) in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Methods This was a single-arm, open-label, phase 2 trial, done at a single tertiary health-care centre in Beijing, China. Women (18–70 years) with high-risk (International Federation of Gynecology and Obstetrics score ≥7) chemorefractory or relapsed gestational trophoblastic neoplasia who had received at least two lines of previously unsuccessful multidrug chemotherapy regimens and had an Eastern Cooperative Oncology Group performance status of 0–2 were eligible for inclusion. Patients received 4-week cycles of intravenous camrelizumab 200 mg every 2 weeks plus oral apatinib 250 mg once per day until disease progression or unacceptable toxicity. The primary endpoint was objective response rate assessed according to serum human chorionic gonadotrophin concentration. Activity and safety were analysed in all patients who received at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov , NCT04047017 . Findings Between Aug 7, 2019, and March 18, 2020, 20 patients enrolled; 19 (95%) were diagnosed with choriocarcinoma and one (5%) had placental site trophoblastic tumour. The median follow-up duration was 18·5 months (IQR 14·6–20·9). The objective response rate was 55% (95% CI 32–77); ten (50%; 95% CI 27–73) patients had complete response. The most common grade 3 treatment-related adverse events were hypertension (five [25%] patients), rash (four [20%] patients), neutropenia (two [10%]), leukocytopenia (two [10%]), and aspartate aminotransferase increase (two [10%]). One patient had a treatment-related serious adverse event (aspartate aminotransferase 19-times higher than the upper limit of normal). No grade 4 or 5 treatment-related adverse events were reported. Interpretation Camrelizumab plus apatinib showed promising antitumour activity and acceptable toxicity and could be a salvage therapy option for the treatment of high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Immune checkpoint inhibitors combined with chemotherapy for heavily-treated patients and upfront use of camrelizumab plus apatinib for patients with high-risk gestational trophoblastic neoplasia are under investigation in phase 2 trials. Funding National Natural Science Foundation of China, Jiangsu Hengrui Pharmaceuticals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|